BRIEF published on 11/04/2024 at 15:20, 1 year 1 month ago LIBRA Insurance Partners Appoints Kelly Anonson as SVP of Business Development Business Development Strategic Growth LIBRA Insurance Kelly Anonson Insurance Partnerships
BRIEF published on 11/04/2024 at 15:20, 1 year 1 month ago LIBRA Insurance Partners nomme Kelly Anonson au poste de vice-présidente senior du développement commercial Croissance Stratégique Développement Des Affaires Kelly Anonson Assurance LIBRA Partenariats D'assurance
PRESS RELEASE published on 11/04/2024 at 15:15, 1 year 1 month ago LIBRA Insurance Partners Names Kelly Anonson as Senior Vice President of Business Development LIBRA Insurance Partners appoints Kelly Anonson as SVP Business Development to lead growth and partnerships, leveraging her 20 years of industry experience Insurance Industry Business Development Strategic Growth Kelly Anonson LIBRA Insurance Partners
Published on 12/05/2025 at 02:35, 4 hours 47 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 6 hours 22 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 8 hours 17 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 8 hours 22 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 07:00, 22 minutes ago Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Published on 12/05/2025 at 03:30, 3 hours 52 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 7 hours 31 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 57 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 11 hours 7 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 18:14, 13 hours 7 minutes ago Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 13 hours 22 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Published on 12/04/2025 at 18:00, 13 hours 22 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 13 hours 37 minutes ago Informations relatives au nombre total de droits de vote et d’actions
Published on 12/04/2025 at 17:45, 13 hours 37 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
